FDA Approves Opdivo to Treat Advanced Form of Kidney Cancer
The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced renal cell carcinoma. As per IQ4I analysis, Mab commanded the largest revenue of $XX million of the immunotherapeutics global market in 2014. For more info http://iq4i.com/www/home/news or email us at bd@iq4i.com